Skip to content
Search

Investment involves risk. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.

Australian Unit Trust
Global Equity Fund
High conviction, global equity portfolio seeking to invest in companies with above-average and sustainable growth characteristics.

Class S PDS

Class I PDS

Client Fund Profile
APIR ETL0071AU
PERFORMANCE REPORT
PDS
QUARTERLY REVIEW
Exit Icon

The Quarterly Review report is not available. Please check back soon.

OK
TMD
Exit Icon

The performance report as of the previous month end is not available. Please check back soon.

Exit Icon

The Product Disclosure Statement for this fund is not currently available. Please check back soon.

31-Oct-2024 - Scott Berg, Portfolio Manager,
We are now in a different part of the interest rate cycle with the U.S. Federal Reserve cutting rates, which could create new opportunities as we see different stock winners and losers as a result. We are encouraged by the resiliency of our portfolio and are optimistic heading into the latter part of the year.

Overview
Strategy
Fund Summary
High conviction, truly global equity portfolio seeking to invest in companies with above-average and sustainable growth characteristics.
Performance - Net of Fees

Past performance is not a reliable indicator of future performance.

31-Oct-2024 - Scott Berg, Portfolio Manager,
In Australian dollar terms, global equities generated solid gains in October as a weakening Australian dollar versus other major currencies helped boost results for Australian investors. Overall, markets wrestled with strong economic data in the U.S. diminishing expectations for more interest rate cuts, signs of deceleration in artificial intelligence demand, China stimulus scepticism, and geopolitical uncertainty. Within the portfolio, our holdings in consumer staples contributed the most to relative returns. Shares of a small format convenience store operator rose over the period, bucking broader weakness in the Indonesian market. We continue to have high conviction in the company and believe the firm has the potential to deliver strong earnings growth, driven by expansion of both margins and stores. Conversely, stock selection in health care hurt relative results. Shares of a leading global bio-analysis company specialising in food, environmental, pharmaceutical products, and clinical diagnostics testing sold off after it reported mixed earnings results, with worse-than-expected core organic growth. However, management raised margin guidance while earnings and free cash flow guidance remained unchanged. We continue to think the company has a one-of-a-kind platform and should deliver strong, durable growth over the long term.
31-Jan-2024 - Scott Berg, Portfolio Manager,
We have an overweight position in financials. We currently have exposure to what we believe are high-quality U.S. banks but are meaningfully underweight European and Japanese peers that broadly have more negative credit exposure. We have a greater allocation to insurance companies than we have typically had in the past, as an improving pricing environment and better yields on portfolio investments have created a positive near- and medium-term setup. We continue to own several emerging market financials that we believe are undervalued and underappreciated and have exposure to high-quality alternative asset managers and leading capital markets companies.

Benchmark Data Source: MSCI. MSCI index returns are shown with reinvestment of dividends after the deduction of withholding taxes. MSCI and its affiliates and third party sources and providers (collectively, “MSCI”) makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

 

The specific securities identified and described in this website do not represent all of the securities purchased or sold for this fund. This information is not intended to be a recommendation to take any particular investment action and is subject to change. No assumption should be made that the securities identified were or will be profitable.

Unless otherwise specified, all fund ratings, awards and data are as of 31-Oct-2024 and sourced from T. Rowe Price. 

©2023 Morningstar, Inc. All rights reserved. The information  contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Equity Trustees Limited (“Equity Trustees”) (ABN 46 004 031 298 AFSL 240975) is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Stock Exchange (ASX:EQT). Equity Trustees and T. Rowe Price Australia Limited ("TRPAU") (ABN: 13 620 668 895 and AFSL: 503741) are, respectively, the responsible entity and investment manager of the T. Rowe Price Australian Unit Trusts. A Target Market Determination for each T. Rowe Price Australian Unit Trust (or class of units in a Trust) is available here (http://www.eqt.com.au/insto). It describes who the financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where Equity Trustees Limited, the responsible entity of the T. Rowe Price Australian Unit Trusts may need to review the Target Market Determination for the financial product.

For Wholesale Clients only.

Past performance is not a reliable indicator of future performance. The price of any fund may go up or down. Investment involves risk including a possible loss to the principal amount invested. For general information purposes only, does not take into account the investment objectives, financial situation or needs of any particular investor. For further details, please refer to each fund's product disclosure statement and reference guide which are available from Equity Trustees (www.eqt.com.au/insto) or TRPAU (www.troweprice.com.au).

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.